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An Integrated Clinico-transcriptomic Approach Identifies a
Central Role of the Heme Degradation Pathway for Septic
Complications After Trauma
Daniel Rittirsch, MD, Veit Schoenborn, MD, Sandro Lindig, PhD,y Elisabeth Wanner, MD,
Kai Sprengel, MD, Sebastian Gu¨nkel, MD, Markus Blaess, PhD,yz Barbara Schaarschmidt, MSc,yz
Patricia Sailer, Sonja Ma¨rsmann, Hans-Peter Simmen, MD, Paolo Cinelli, PhD,
Michael Bauer, MD,yz Ralf A. Claus, PhD,yz and Guido A. Wanner, MD
Objective: The present study was aimed to identify mechanisms linked to
complicated courses and adverse events after severe trauma by a systems
biology approach.
Summary Background Data: In severe trauma, overwhelming systemic
inflammation can result in additional damage and the development of
complications, including sepsis.
Methods: In a prospective, longitudinal single-center study, RNA samples
from circulating leukocytes from patients with multiple injury (injury severity
score 17 points; n¼ 81) were analyzed for dynamic changes in gene
expression over a period of 21 days by whole-genome screening (discovery
set; n¼ 10 patients; 90 samples) and quantitative RT-PCR (validation set;
n¼ 71 patients, 517 samples). Multivariate correlational analysis of tran-
scripts and clinical parameters was used to identify mechanisms related to
sepsis.
Results: Transcriptome profiling of the discovery set revealed the strongest
changes between patients with either systemic inflammation or sepsis in gene
expression of the heme degradation pathway. Using quantitative RT-PCR
analyses (validation set), the key components haptoglobin (HP), cluster of
differentiation (CD) 163, heme oxygenase-1 (HMOX1), and biliverdin
reductase A (BLVRA) showed robust changes following trauma. Upregulation
of HP was associated with the severity of systemic inflammation and the
development of sepsis. Patients who received allogeneic blood transfusions had
a higher incidence of nosocomial infections and sepsis, and the amount of blood
transfusion as source of free heme correlated with the expression pattern of HP.
Conclusions: These findings indicate that the heme degradation pathway is
associated with increased susceptibility to septic complications after trauma,
which is indicated by HP expression in particular.
Keywords: heme degradation pathway, multiple injury, sepsis, systemic
inflammation, transcriptome profiling, trauma
(Ann Surg 2015;xx:xxx–xxx)
M ultiple trauma still represents one of the leading causes ofdeath in western countries, and treatment of severely injured
patients imposes a considerable burden for healthcare systems.1–3
Severe trauma triggers systemic inflammation, the clinical presen-
tation of which is indistinguishable from sepsis syndrome, but not
necessarily associated with infection.4,5 Already decades ago, it has
been demonstrated that multiorgan failure (MOF) frequently
occurred in trauma patients without infection.6 While the overall
mortality rate from multiple trauma has declined significantly, the
incidence of secondary sepsis after trauma remained unchanged
during the past decade and represents a dreaded complication with
prolonged necessity of intensive care and an unfavorable outcome.1
The incidence of MOF induced by traumatic shock has decreased
substantially, whereas a decrease in MOF incidence due to sepsis is
not observed.1 The decrease in inhospital mortality from severe
trauma was inter alia achieved because the underlying patho-
physiology is reflected by current treatment concepts, including
damage control surgery and evidence-based protocols for fluid
resuscitation, blood transfusion, and the management of traumatic
coagulopathy.7–9 With the definition of sepsis criteria in the 1990s, it
has been conceptualized that the immune response after trauma
follows a biphasic course with an early hyperinflammation (systemic
inflammatory response syndrome; SIRS) that is terminated by
immunosuppression during the later course (compensatory anti-
inflammatory response syndrome).10,11 In this concept, MOF was
thought to be either induced by an overwhelming initial insult (‘‘one-
hit model’’) or SIRS was amplified by a second insult (eg, surgical
intervention; ‘‘two-hit model’’).5,10,12 Recently published findings of
the Glue Grant Consortium on leukocyte genomic expression pat-
terns showed the simultaneous induction of a plethora of pro- and
anti-inflammatory genes after trauma, whereas adaptive immunity-
associated genes were found to be suppressed. Based on these data, a
novel model (‘‘genomic storm’’) has been derived, which challenges
the second hit theory of the traditional SIRS—compensatory anti-
inflammatory response syndrome paradigm, as the response of
patients with different courses after trauma was found to be more
common than different.5,13 Although recent research has improved
our understanding of the network of systemic inflammation, the
mechanisms that lead to adverse events, including nosocomial
infections, MOF, and sepsis are inadequately understood, and
specific immune-modulatory therapies are still far from reach for
the treatment of trauma patients.12,14
From the Division of Trauma Surgery, Department of Surgery, University
Hospital Zurich, University of Zurich, Zurich, Switzerland; yDepartment of
Anaesthesiology and Intensive Care Therapy, Jena University Hospital, Jena,
Germany; and zCenter for Sepsis Control and Care, Jena University Hospital,
Jena, Germany.
All authors contributed equally.
All authors jointly supervised this study.
This work was partly supported by grants from the Stiftung fu¨r Wissenschaftliche
Forschung of the University of Zurich, the German Federal Ministry of
Education and Research (BMBF), grant 01EO1002 to the Center for Sepsis
Control and Care, grant 03Z2J521 to Meta-ZIK, and from the German
Research Foundation DFG, Forschergruppe 1738, hhdp – heme and heme
degradation products, alternative functions, and mechanisms.
Supplemental digital content is available for this article. Direct URL citations
appear in the printed text and are provided in the HTML and PDF versions of
this article on the journal’s Web site (www.annalsofsurgery.com).
The authors report no conflicts of interest.
Reprints: Guido A. Wanner, Division of Trauma Surgery, Department of Surgery,
University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland.
E-mail: guido.wanner@usz.ch.
Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN: 0003-4932/14/26105-0821
DOI: 10.1097/SLA.0000000000001553
Annals of Surgery  Volume XX, Number X, Month 2015 www.annalsofsurgery.com | 1
ORIGINAL ARTICLE
Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
CE: S.W.; ANNSURG-D-15-00582; Total nos of Pages: 10;
ANNSURG-D-15-00582
In the present study, we aimed to investigate mechanisms of
systemic inflammation after severe trauma by analysis of leukocyte
transcriptomic expression patterns in order to identify pathways that
are associated with infectious complications and sepsis, in particular.
METHODS
Study Design
Blood was sampled from 104 patients with multi-system
trauma admitted to the Division of Trauma Surgery (level I trauma
center) at the University Hospital Zurich from 12/2009 to 03/2012.
Criteria for study enrollment included patient age 18 years, an
Injury Severity Score (ISS) 17 points, and time from injury to
admission <6 hours. All patients were recruited into the study under
informed consent guidelines approved by the Local Ethical Com-
mittee (StV 26–2007) and international ethical guidelines (Clinical-
Trials.gov-Identifier: NCT02508272). Study subjects were treated
under the guidance of standard operating procedures developed and
implemented at the University Hospital Zurich (based on guidelines
of the German Society of Trauma; DGU).15 Whole blood from
trauma patients was collected within the first 6 hours after trauma
(day 0) and on days 1, 2, 3, 5, 7, 10, 14, and 21. Clinical outcomes and
complications within 28 days after injury were recorded. Patient
enrollment and study design are illustrated in Supplemental Fig. 1,
http://links.lww.com/SLA/A929. For discovery, 10 representative
patients (discovery set; n¼ 90 samples) were selected based on their
clinical presentation with respect to the development of secondary
sepsis (n¼ 5 patients; n¼ 45 samples) or systemic inflammation
without infection (n¼ 5 patients; n¼ 45 samples) for whole-genome
screening. After statistical gene selection, results were validated in
the remaining patients of the total cohort (validation set; n¼ 71
patients; n¼ 517 samples) by quantitative RT-PCR.
Clinical Data
Clinical data were prospectively collected in parallel with the
corresponding blood samples. The occurrence and severity of
systemic inflammation, sepsis, MOF, and nosocomial infections
were retrospectively analyzed using the corresponding clinical
parameters from patients’ records. MOF was defined according to
the Sequential Organ Failure Assessment (SOFA) score.16 Systemic
inflammation and sepsis was defined according to criteria of the
current guidelines.17–19 For assessment of the severity of trauma-
induced systemic inflammation and to define secondary sepsis in
trauma patients a scoring system has been applied (SI score; for
details see Supplemental Information, Supplemental Table 1 and
Supplemental Fig. 2, http://links.lww.com/SLA/A929).20–24
RNA Isolation
PaxGene (PreAnalytix, Hombrechtikon, Switzerland) tubes
were used for sampling and preservation of whole blood, and total
cellular RNA from circulating leukocytes was isolated (PaxGene
Blood RNA Kit; PreAnalytix) in a Qiacube apparatus according to
the manufacturer’s instructions. RNA integrity was proven using
Experion (Biorad, Munich, Germany) microcapillary electrophore-
sis. A detailed description of the totRNA quality control and sample
selection criteria is provided in Supplement, http://links.lww.com/
SLA/A929. For cDNA-synthesis, 1mg total RNA per sample was
transcribed (RevertAid First Strand cDNA Synthesis, ThermoFisher
Scientific; PTC-200 Thermal Cycler Dual, BioRad) according to
manufacturer’s protocol.
Microarray Analysis
A total of 200 ng RNA of each sample was reversely trans-
cribed and amplified using the TargetAmp-Nano Labeling Kit for
Illumina Expression BeadChips (Biozym Scientific GmbH, Hessisch
Oldendorf, Germany) according to the manufacturer’s instructions
on a Biorad MJ Thermal Cycler (Biorad). All cRNA samples were
purified the NucleoSpin RNA Clean-up system (Macherey-Nagel,
GmbH & Co. KG, Du¨ren, Germany) and quantified using a Nano-
Drop spectrophotometer ND-2000 (Thermo Fisher Scientific,
Schwerte, Germany/PEQLAB Biotechnologie, Carlsbad, CA) before
proceeding to sample hybridization. Samples were prepared and
hybridized on Illumina Human-HT-12-V4 Expression BeadChips
(Illumina, San Diego, CA, USA; for details see Supplemental
Information, http://links.lww.com/SLA/A929). For posthybridiza-
tion data read-out and data preprocessing, including spot detection,
gene mapping, and averaging of replicates, iScan Control Software
was used. Control probe quality check was performed using Illumina
Genome Studio-Software.
Statistical analysis (for details see Supplement, http://links.
lww.com/SLA/A929) was performed using R software (http://
www.r-project.org/) and packages from Bioconductor.25 Differen-
tially expressed genes were filtered by exhibiting above median-
averaged 1.5-fold change, estimate of significance P 0.05 and a
false discovery rate <0.05. Candidate genes selected for further
analysis and validation by quantitative real-time PCR were identified
by gene-set enrichment analysis (list is provided in Supplemental
Table 5, http://links.lww.com/SLA/A929).
Quantitative RT-PCR
RT-qPCR was performed in a two-step protocol using Rotor-
Gene system and Rotor-Gene SYBR Green PCR Kit (Qiagen,
Hilden, Germany) according to manufacturer’s information with
250 nM Primer mix and 25 ng cDNA. Initial denaturation at 958C
for 5minutes, followed by 50 cycles of denaturation at 958C for
5 seconds and annealing/extension at a given temperature (see table)
for 15 seconds, finally followed by a melting curve. Ct values and
efficiency were documented for each sample, data were normalized
to unchanged transcripts, whereby housekeeper adjustment (DCt)
was performed via expressed ACTB [DCt¼Ct(ACTB) - Ct(Candi-
date)]. The primer sequences are listed in Supplemental Table 2,
http://links.lww.com/SLA/A929. No Ct values of genes with signifi-
cant increases/decreases as well as reference genes included in this
study were detected above 26 cycles. Comparisons of PCR values for
the various groups are displayed in Box-and-Whisker plots. Signifi-
cance was attained at P < 0.05 using the Mann-Whitney U (Wil-
coxon rank sum) test. Similarity was assessed using parametric (r)
and nonparametric (r) measures. Influences of clinical variables and
their interactions on gene expression were investigated using
multivariate ANOVA.
RESULTS
Transcriptome Profiling for Hypothesis Generation
Characteristics of the patient cohort are displayed in Table 1
(for further details see Supplemental Information and Supplemental
Table 3, http://links.lww.com/SLA/A929).
In a discovery set, RNA samples from 10 representative
trauma patients (all time points) diagnosed with either secondary
sepsis or systemic inflammation without infection, respectively, were
analyzed by whole-genome screening of differential gene expression
patterns. Using unsupervised clustering, patients with systemic
inflammation only and sepsis patients showed a distinct expression
pattern and the discrimination of clinical presentation (Fig. 1A).
Explorative gene-set analysis revealed robust upregulation of genes
related to ‘‘hemoglobin metabolism/oxygen transport’’ and ‘‘patho-
genic Escherichia coli infection,’’ whereas the strongest downregu-
lation was found for ‘‘ribosome-associated genes’’ (Table 2).
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TABLE 1. Patient Characteristics
Parameter Total Cohort (n¼ 104 patients) Discovery Set (n¼ 10 patients) P
Demographics
mean  SEM; median (min.-max.) meanSEM; median (min.-max.)
Age (yr) 43.5 1.77; 42 (18–92) 41 4.9; 42 (20–62) 0.85; ns
Sex (male/female) 77/27 8/2
GCS 11.9 0.41; 14 (3–15) 12.8 1.2; 14.5 (5–15) 0.58; ns
Traumatic brain injury 38/104 (36.5%) 2/10 (20%)
AIS max. 4.1 0.1; 4 (2–6) 4.6 0.2; 5 (3–5)
AIS Head/neck/cervical spine 2.2 0.2; 2 (0–6) 1.5 0.5; 1 (0–5)
AIS Face 0.7 0.1; 0 (0–3) 0.5 0.2; 0 (0–2)
AIS Thorax/thoracic spine 2.9 0.2; 3 (0–5) 3.3 0.5; 3.5 (0–5)
AIS Abdomen/lumbar spine 1.9 0.2; 2 (0–5) 3.2 0.2; 3.5 (0–5)
AIS Upper/lower Extremitiy 2.4 0.1; 3 (0–5) 2.5 0.4; 3 (0–5)
AIS Integument 0.4 0.1; 0 (0–3) 0.7 0.3; 0 (0 -2)
ISS 32.8 1.3; 31 (17–75) 37.5 2.3; 36 (27–50) 0.07; ns
SOFA score initial 4.8 0.3; 5 (0–12) 5.5 0.9; 6.5 (0–9) 0.45; ns
SOFA score max. 7.7 0.4; 8 (0–18) 10.9 1.4; 12 (1–16) <0.05
Outcomes
RISC (% survival) 83.3 2.5 88.6 3.5; 94.2 (71.1–97.6) 0.79; ns
Survival 88% (13 nonsurvivors) 100%
Hospital length of stay (d) 26.6 1.8; 21.5 (2–119) 40.4 6.0; 42.5 (17–82) <0.01
Intensive care unit length of stay (d) 13.9 1.4; 10 (2–86) 27.4 7.4; 19.5 (6–86) <0.05
Allogeneic blood transfusion
TASH score (points) 8.5 0.6; 8 (0–23) 11.3 2.5; 10 (2–22) 0.22; ns
TASH (%) 13.9 2.0 22.1 10.6; 8 (5–77) 0.14; ns
Initial (d0) pRBC transfusion (units) 4.0 0.8; 1 (0–54) 11.3 5.3; 4 (0–54) <0.05
Total pRBC transfusion (units) 9.6 1.3; 5 (0–70) 21.2 8.0; 9 (3–70) <0.05
Massive transfusion rate 13.5% 30%
Infectious complications
Nosocomial infections 56/104 (53.9%) 5/10 (50%)
Sepsis 15/104 (14.0%) 5/10 (50%)
Parameter Discovery set (n¼ 10 patients) P-value
Systemic inflammation (n¼ 5) Sepsis (n¼ 5)
Demographics
meanSEM; median (min.-max.) meanSEM; median (min.-max.)
Age (yr) 34 6.5; 28 (20–58) 48 6.4; 47 (26–62) 0.21; ns
Sex (male/female) 4/1 4/1
GCS 12.6 1.9; 14 (5–15) 13 1.6; 15 (7–15) 0.82; ns
Traumatic brain injury 2/5 (40%) 0/5 (0%)
AIS max. 4.4 0.4; 5 (5–3) 4.8 0.2; 5 (4 -5)
AIS Head/neck/cervical spine 2 0.9; 2 (5–0) 1 0.5; 1 (0–3)
AIS Face 0.6 0.4; 0 (2–0) 0.4 0.2 0 (0–1)
AIS Thorax/thoracic spine 2.6 0.9; 3 (0–5) 4 0.5; 4 (3–5)
AIS Abdomen/lumbar spine 2.8 0.9; 3 (0–5) 3.6 0.7; 4 (2–5)
AIS Upper/lower Extremitiy 2.2 0.4; 2 (1–3) 2.8 0.8; 3 (0–5)
AIS Integument 1 0.5; 1 (0–2) 0.4 0.4; 0 (0–2)
ISS 33.8 2.0; 33 (27–38) 41.2 3.7; 38 (34–50) 0.14; ns
SOFA score initial 4.8 1.0; 5 (1–7) 6.2 1.6; 7 (0–9) 0.20; ns
SOFA score max. 7.8 1.8; 9 (1–12) 14 0.6; 14 (12–16) <0.05
Outcomes
RISC (% survival) 92.4 4.1; 96.7 (76.1–97.6) 83.9 5.6; 83.4 (71.1–97.6) 0.38; ns
Survival 100% 100%
Hospital length of stay (d) 27 4.1; 25 (17–42) 53.8 7.3; 49 (43–82) <0.05
Intensive care unit length of stay (d) 17.4 6.4; 12 (6–42) 37.4 12.5; 26 (18–86) 0.10; ns
Allogeneic blood transfusion
TASH score (points) 8.6 2.2; 10 (2–15) 18 4; 18 (14–22) 0.17; ns
TASH (%) 11 4.6; 8 (5–29) 50 27; 50 (23–77) 0.17; ns
Initial (d0) pRBC transfusion (units) 2.6 0.8; 3 (0–5) 20.9 9.4; 19 (0–54) 0.12; ns
Total pRBC transfusion (units) 6.8 0.9; 6 (5–9) 35.6 13.7; 24 (3–70) 0.14; ns
Massive transfusion rate 0% 60%
Infectious complications
Nosocomial infections 0/5 (0%) 5/5 (100%)
Sepsis 0/5 (0%) 5/5 (100%)
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Moreover, principle component analysis also revealed distinct
expression patterns of patients with sepsis and patients with systemic
inflammation without infection, and indicated an extraordinary role
of haptoglobin (HP) in patients with sepsis among all genes analyzed
(Fig. 1B). In line with the findings of the discovery set, re-investi-
gation of data sets from external, independent cohorts also identified
HP among top 10 upregulated genes in patients who developed sepsis
in comparison to healthy controls or patients with SIRS without
infection by one-way ANOVA (P< 10–12).26
For further analysis, expression of the key components of the
heme degradation pathway HP (Fig. 1C), cluster of differentiation
163 (CD163; Fig. 1D), heme oxygenase-1 (HMOX1; Fig. 1E), and
biliverdin reductase A (BLVRA; Fig. 1F) was quantified. All genes
of the heme degradation pathway showed a similar pattern with
significant upregulation in patients with sepsis as compared to
patients with systemic inflammation without infection, as for nor-
malization to time point d0 (Fig. 1C–F) or when comparing absolute
expression values (Fig. 1G and H). Furthermore, these expression
TABLE 2. Explorative Gene-Set Analysis
Knowledge Base Category Name # Hits
P-value
(Fisher Exact Test)
FDR-adjusted
P (Benjamini-Hochberg)
Upregulated genes: average log2FC (sepsis versus systemic inflammation) >0.5
Gene Ontology CC Hemoglobin complex 10 1.60E-11 6.00E-09
Swiss Prot Oxygen transport 8 2.10E-08 3.50E-06
KEGG PATHWAY Pathogenic E. coli infection 8 2.90E-06 4.00E-04
Gene Ontology BP Hemoglobin metabolic process 5 3.00E-04 5.80E-02
Downregulated genes: average log2FC (sepsis versus systemic inflammation) < 0.5
Gene Ontology BP Translational elongation 26 5.00E-14 6.90E-11
Swiss Prot Protein biosynthesis 31 1.30E-12 3.00E-10
KEGG PATHWAY Ribosome 25 2.20E-12 3.30E-10
Gene Ontology BP Defense response 65 2.40E-13 2.20E-10
FIGURE 1. Whole-genome analysis of circulating leukocytes from trauma patients (n¼90 samples; 10 patients; all time points: day
0, 1, 2, 3, 5, 7, 10, 14, 21) who clinically either presented with systemic inflammation without infection (n¼5) or sepsis (n¼5). (A)
Unsupervised cluster analysis (Pearson correlation; LFC values). (B) Principal component analysis characterizing differential gene
expression profiles of trauma patients. Quantification of expression (logarithmic fold change, LFC; adjusted to day 0) of HP (C),
CD163 (D), HMOX1 (E), BLVRA (F), and absolute expression values for HP (G) and BLVRA (H), comparing patients with systemic
inflammation or sepsis. P<0.05; NS¼not significant.
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patterns were confirmed by external validation of two independent
cohorts (datasets: GPSSSI unique and GSE9960) of a recent
multicohort analysis, comparing patients with sterile inflammation
(SIRS/trauma) to time-matched patients with infections by whole-
genome screening (Supplemental Fig. 3, http://links.lww.com/SLA/
A929).26–28
Effect of Allogeneic Blood Transfusion on Clinical
Outcome Parameters
Based on the results from whole-genome screening of the
discovery set, samples from all patients with complete clinico-
transcriptomic coverage (n¼ 71; 517 samples) were analyzed for
gene expression patterns of HP, CD163, HMOX1, BLVRA, and
BLVRB by quantitative RT-PCR normalized to the housekeeping
gene ACTB (DCt). In a first step, unsupervised clustering was
applied to clinical parameters and expression of the key components
of the heme degradation pathway. As shown in Fig. 2A, HP clustered
with BLVRA. As to be expected, the total blood transfusion rate
(pRBC-total) correlated with the Trauma Associated Severe Hem-
orrhage (TASH) score and the hematocrit (Fig. 2A). Among the
scoring systems, the RISC score negatively correlated with the ISS,
the New Injury Severity Score (NISS), and the SOFA score (Fig. 2A).
Interestingly, HP, CD163, HMOX1, BLVRA, and BLVRB collec-
tively clustered with the ICU length of stay (ICU-LOS). Since the
heme degradation pathway is activated by free heme, the initial and
total amount of packed red blood cells (pRBCs) transfusion was
assessed for various outcome parameters. Trauma patients who
developed nosocomial infections received more units of pRBCs
(initial¼ at the day of trauma; as well as total) than patients without
infection (Fig. 2B). These differences in the amount of allogeneic
blood transfusion were even more striking in sepsis patients as
compared to trauma patients who did not develop secondary sepsis
(Fig. 2C). In contrast, there was no difference in the initial and total
volume of allogeneic blood transfusion in patients who did not
survive in comparison to survivors (Fig. 2D).
In the present patient cohort, the TASH score as a measure for
the risk of massive blood transfusion (10 pRBC within 24 hours)
matched with the actual mass transfusion rate (Table 1). In accord-
ance with Fig. 2B and C, trauma patients with nosocomial infections
or sepsis had significantly higher TASH scores than patients without
infectious or septic complications (Fig. 2E and F).
Furthermore, the volume of allogeneic blood transfusion
correlated with the ICU-LOS, as displayed in Fig. 2G for the total
amount as well as for the initial amount of pRBC administered
FIGURE 2. Correlation of clinical parameters of trauma patients (n¼52) and expression of heme degradation pathway expression
(DCt of HP, CD163, HMOX1, BLVRA, and BLVRB) (A). Association of transfusion of packed red blood cells (pRBCs; total vs. initial
amount¼ at day 0) with nosocomial infections (B), sepsis (C), and survival (D). Comparison of TASH scores of patients with
nosocomial infections (E) or sepsis (F) to trauma patients without infectious complications. N¼104; P<0.05; NS¼not significant.
Correlation of the total amount of pRBC transfusion of with the ICU-LOS (G) and ISS (H). Initial amount of pRBC transfusion is color
coded (blue represents 4 units; red represents >4 units).
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(Spearman correlation coefficient r [total pRBC]¼ 0.55; r [initial
pRBC]¼ 0.39). However, there was also an association between the
amount of pRBC transfusion and the ISS (Fig. 2H; r [total
pRBC]¼ 0.43; r [initial pRBC]¼ 0.44). Similarly, trauma patients
who developed nosocomial infections or sepsis had higher ISS than
patients without infections or sepsis, respectively (Supplemental
Fig. 4A and B, http://links.lww.com/SLA/A929). With respect to
massive blood transfusion, higher TASH scores were associated
with higher ISS (Supplemental Fig. 4C, http://links.lww.com/SLA/
A929). However, there was no significant difference in the ISS in
patients who did not receive allogeneic blood transfusion at all in
comparison to patients who received 1 unit of pRBC or more
(Supplemental Fig. 4D, http://links.lww.com/SLA/A929). Notably,
none of the patients without allogeneic blood transfusion developed
secondary sepsis.
Analysis of the Expression Patterns of the Heme
Degradation Pathway
Cluster analysis of the expression of HP, CD163, HMOX1,
and BLVRA as determined by microarray (discovery set; Fig. 3A) or
quantitative real-time PCR (validation set; Fig. 3B) in which samples
were arranged according to the clinical presentation of sepsis or
systemic inflammation revealed a distinct expression pattern of HP
in sepsis.
Correlation of Heme Degradation Pathway
Expression with Changes in the Severity of
Systemic Inflammation and the
Development of Sepsis
For further correlational analysis of gene expression data with
the clinical course, the SI score for assessment of the severity of
systemic inflammation has been applied. As shown in Fig. 4, expres-
sion patterns of components of the heme degradation pathway
followed the clinical course (SI score). Whereas shifts toward
increased severity of systemic inflammation was associated with
an upregulation of the heme degradation pathway components HP
(Fig. 4A; ANOVA P< 1010, r [SI score, HP]¼ 0.44) and HMOX1
(Fig. 4C), the expression of BLVRA (Fig. 4D) was downregulated
with increasing SI score. These linear trends were most profound for
the expression of HP (Fig. 4A). With respect to the hierarchy of the
heme degradation cascade, the ratio of BLVRA and HMOX1
decreased with increasing SI score, suggesting that BLVRA becomes
the rate-limiting step in higher grades of systemic inflammation
(Fig. 4E). Moreover, the strongest upregulation of HP expression was
found in patients who were diagnosed with sepsis (Fig. 4F), further
corroborating the association between expression of the heme degra-
dation pathway and the development of sepsis. In these patients,
aggravation of systemic inflammation (positive DSI score) was
accompanied by an upregulation of HP expression, whereas
FIGURE 3. Correlation (cluster analysis) of the expression of HP, CD163, HMOX1, and BLVRA of the discovery set (A; microarray;
n¼90 samples; 10 patients; all time points) and the validation set (B; quantitative RT-PCR; n¼517 samples; 71 patients; all time
points) arranged by clinical presentation: sepsis vs. systemic inflammation.
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attenuation (negative DSI score) went along with downregulation of
HP (Fig. 4G).
Interestingly, an increasing risk for massive transfusion
(TASH score) was reflected by an upregulation of HP (Fig. 4H),
whereas there were no changes in the expression of HMOX1
(Fig. 4I). As a possible explanation for the latter observation, there
was a strong gender effect on the expression of HMOX1 (Fig. 4J).
Similar to the TASH score, HP expression but not HMOX1 correlated
with the amount of allogeneic blood transfusions (number of total
pRBCs; Fig. 4K and L). In accordance, systematic, multivariate
factorial analysis (MANOVA; Supplemental Table 4, http://links.
lww.com/SLA/A929) showed that HP positively correlated with the
rate of allogeneic blood transfusions, SI score, and sepsis. Similarly,
HMOX1 expression was influenced by the total amount of pRBCs
and associated with sepsis. Interestingly, these analyses showed
significant time effects for BLVRA and CD163. A complete list
of P values is provided in Supplemental Table 4, http://links.
lww.com/SLA/A929.
In further correlational analyses of heme degradation pathway
expression and various mediators of inflammation (Supplemental
Fig. 5, http://links.lww.com/SLA/A929), HP expression showed a
stronger positive correlation with the anti-inflammatory cytokine IL-
10 than with the pro-inflammatory mediators IL-8 or TNF-a,
suggesting that upregulation of the heme degradation pathway
may be related to a rather anti-inflammatory phenotype.
Temporal Relationship between Gene Expression
and the Development of Sepsis
In order to depict temporal changes of heme degradation
pathway gene expression relative to clinical events, trajectories of
septic patients were plotted in relation to the expression of the
total cohort (discovery set: Fig. 5; Supplemental Fig. 6, http://
links.lww.com/SLA/A929; validation set: Supplemental Figs. 7
and 8, http://links.lww.com/SLA/A929). Although the courses
were found to be highly individual for each patient, collectively,
administration of allogeneic blood was followed by an upregu-
lation of heme degradation pathway expression, and continuous
increases or secondary peaks preceded the clinical diagnosis
of sepsis.
FIGURE 4. Expression (DCt) of HP (A), CD163 (B), HMOX1 (C), and BLVRA (D) in correlation with the severity of systemic
inflammation (SI score). Significance, using P<0.05 from ANOVA and strong linear and nonlinear correlation (rho > 0.4) was
obtained for HP. (E) Hierarchical relationship between HMOX1 and BLVRA in correlation with the SI score. (F) Expression of HP (DCt)
in trauma patients with sepsis as compared to patients without sepsis. (G) Correlation of changes in HP expression (DDCt¼differ-
difference between consecutive time points) with corresponding changes in severity of systemic inflammation (DSI score).
Association of the TASH score with the expression (DCt) of HP (H) and HMOX1 (I). (J) Influence of gender on HMOX expression
(DCt). Relationship between the amount of allogeneic blood transfusions (log number of total pRBCs) and the expression (DCt) of
HP (K) and HMOX1 (L). N  51 patients. P<0.05.
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DISCUSSION
The present study demonstrates for the first time that the heme
degradation pathway is differentially regulated after multiple trauma
and is associated with septic complications. The expression of HP in
particular indicates the severity of systemic inflammation and
represents a promisingmarker for secondary sepsis in trauma patients.
Our data suggest that the heme degradation pathway is
triggered by free heme released from allogeneic blood transfusions
after hemorrhagic shock, which was also associated with a signifi-
cantly higher incidence of nosocomial infections and sepsis and a
prolonged stay on the ICU. This is in line with several previous
studies reporting that the transfusion of allogeneic blood represents
an independent risk factor in critically ill patients for the develop-
ment of infectious complications, MOF, and even mortality.1,12,29–33
With respect to the latter, a recent study demonstrated that only
patients with a high risk of death due to traumatic hemorrhagic shock
benefit from pRBC transfusions, whereas mortality is increased in
trauma patients with a low risk of death.33 In our cohort, the
expression patterns of the heme degradation pathway did not corre-
late with mortality, suggesting that the transcriptomic signatures are
specific for the development of secondary sepsis in trauma patients
but do not relate to an adverse outcome in general. Both the TASH
score and amount of pRBC transfusion correlated with the
development of sepsis and the HP expression pattern, corroborating
the relationship between blood transfusion, regulation of the heme
degradation pathway, and the development of sepsis. However, due to
the clinical–translational nature of the study and multiple dependent
variables, causal pathophysiologic relationships are difficult to inter-
pret, and it remains unclear whether the changes of gene expression
are secondary to blood transfusions or to the condition of hemor-
rhagic shock itself.
It is well established that pRBCs can undergo nonimmuno-
logic hemolysis due to mechanical injury of RBCs and/or RBC
storage lesions, resulting in an increased cellular fragility. Depending
on the age of the pRBC product, up to 25% of the RBCs undergo
nonimmunologic hemolysis within 24 hours after transfusion, result-
ing in a considerable amount of heme.34 In experimental sepsis, free
heme has been described to play a central role by compromising the
host tolerance to infection.35 Based on findings of the present study
and published mechanisms of the heme degradation pathway, we
conceptualize the pathophysiology in trauma as follows: free heme
released from hemoglobin after allogeneic blood transfusions
represents a robust proinflammatory stimulus and functions as a
danger-associated molecular pattern, but it also exerts cytotoxic
effects.36–38 In order to neutralize free heme, the heme-degradation
pathway is activated, which may shift the balance of the immune
response toward an anti-inflammatory phenotype.39 HP as the
FIGURE 5. Temporal relationship of the expression of HP (A) CD163 (B), HMOX1 (C), and BLVRA (D) with the clinical course. The
individual course of each patient with sepsis (n¼5) of the discovery set (n¼90 samples; 10 patients) are plotted as trajectories in
different colors. The time points of diagnosis of sepsis are indicated by the arrows on the top of each figure. The amount of
allogeneic blood transfusions (number of pRBCs) is indicated at specific time points for each patient.
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immediate interaction partner of free heme and HMOX1 as the rate-
limiting step of the enzymatic heme degradation cascade represent
key components of the heme degradation pathway and are known as
key regulators of the immune response.35,40–43 Prolonged dysregu-
lation of the heme-degradation pathway may contribute to an
increased susceptibility of secondary infections and the development
of sepsis. On the contrary, it is conceivable that in the case of an
overwhelming release of free heme, mechanisms for neutralization
and degradation of heme may become saturated, resulting in remote
tissue damage by circulating free heme and a reduced tolerance to
infection. Experimental and clinical studies suggest that HMOX1 is
the rate-limiting step of heme degradation, and that its genotypes and
underlying regulatory mechanisms are associated with the outcome
in sepsis.44–47
The particular design of the present study with purposeful
selection of patients for the discovery set (secondary sepsis vs.
systemic inflammation without infection) and consecutive validation
of candidates in the total cohort by an independent method has been
conceptualized to overcome possible masking effects by ‘‘non-selec-
tive’’ whole-genome screening of all patients. In contrast to our results,
gene expression patterns in a similar trauma patient cohort in a
previous study by the Glue grant consortium were found to be more
common than different in patients with ‘‘complicated’’ or ‘‘uncom-
plicated recovery.’’13 As a matter of speculation, this rather unspecific
distribution of patients into subgroups might have contributed to
masking of differential gene expression. This assumption is supported
by the fact that HP was also found among the genes whose expression
increased the most in the ‘‘genomic storm’’ study.13 In fact, similar
correlations of heme degradation pathway expression with clinical
variables as in our study were found reanalyzing the publicly available
Glue grant data set (eg, correlation of HP expression with volume of
allogeneic blood transfusions, incidence of nosocomial infections and
SSI, or ICU-LOS; data not shown) and additional data sets of two
independent cohorts that are part of a recent multicohort analysis,
comparing patients with sterile inflammation to sepsis.13,26–28
In our cohort as well as in external data sets, HP expression has
been consistently identified as a promising marker for sepsis in
trauma patients, which may even be superior to and more specific
than serum bilirubin, as HP expression precedes the generation of
bilirubin, and high bilirubin levels can not only be caused by
increased heme degradation but also by impaired hepatic secretion.48
Our data indicate that an integrated clinico-transcriptomic
approach facilitates to distinguish between systemic inflammation
without infection and sepsis after trauma, in accordance with
previous studies in trauma and nontrauma patients with sep-
sis.26,49–51 With respect to the impact on the treatment strategy of
trauma patients, our findings imply that patients who received blood
transfusions should be closely monitored regarding the development
of septic complications using specific markers. In future, routine
evaluation of trauma patients may ideally comprise integrated assess-
ment of clinical, laboratory, proteomic, and transcriptomic
parameters, on the basis of which treatment algorithms, including
timing of secondary surgical interventions as well as operative
techniques to be applied, could be adapted to the individual risk
profile. The expression patterns of the heme degradation pathway in
leukocytes, with HP in particular, may help assess the host immune
status and response and stratify the individual risk of trauma patients
for infectious complications and sepsis.
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